Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices
NHS hospitals in England used £107,069,150 of indicative cost of Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is up 89.3% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Tezepelumab 210mg/1.91ml solution for injection pre-filled disposable devices most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Guy's & St Thomas' Nhs Foundation Trust | £22,099,437 |
| Manchester University Nhs Ft | £7,329,410 |
| University Hospital Southampton Nhs Ft | £5,251,015 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £4,513,520 |
| Aintree University Hospital Nhs Ft | £4,313,650 |
| Oxford University Hospitals Nhs Ft | £3,662,175 |
| University Hpls Of Leicester Nhs Trust | £3,563,505 |
| Barts Health Nhs Trust | £3,525,555 |
| Cambridge Univ Hosp Nhs Foundation Trust | £3,157,440 |
| Univ Hpl B/Ham Nhs Foundation Trust | £3,072,685 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.